REVIVA PHARMACEUT.HLDGS

Reviva Pharmaceuticals announced that trading of its common stock on Nasdaq was suspended by the Nasdaq Hearings Panel for failing to meet the $1.00 minimum bid price, and that the stock will be traded on the OTCQB market under the ticker RVPH starting at market open Thursday. The company warns that the delisting may impair liquidity, market price and its ability to raise capital. Reviva also raised $10 million through a public offering and, after adjustment for a stock split, has provided funds to further develop Brilaroxazin. Additionally, Reviva plans a patent for a new drug formulation that, if granted, could potentially provide protection until 2046. » Plus sur de.investing.com

Reviva Pharmaceuticals has filed a patent application for a new composition of Brilaroxazin and requested an accelerated review that could potentially extend commercial exclusivity through 2046. The company is preparing engagement with the FDA, plans to use the new formulation in the phase‑3 RECOVER‑2 trial, and expects feedback by mid‑2026; study activities are slated to begin in Q2 2026, U.S. patient recruitment in Q3 2026, with completion in Q4 2027. Despite a steep share decline (stock down 96% from its 52‑week high), Reviva highlights a comparatively liquid balance sheet; a recent capital raise brought in about $10 million and a 1:20 reverse split was announced, prompting an analyst downgrade. » Plus sur de.investing.com

Reviva Pharmaceuticals has closed a $10 million financing, raising its cash balance to about $23 million and securing operations through the first quarter of 2027. The funds will support development of the drug candidate Brilaroxazin; Reviva has patented a new formulation and is seeking an accelerated review. The company plans to begin study-related activities for the Phase 3 RECOVER-2 trial in Q2 2026, start patient recruitment in the US in Q3, and complete the study in Q4 2027; FDA feedback is expected by mid-2026. » Plus sur de.investing.com